drugset / Trial / NCT00005834
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
Phase 3
Terminated
19 enrolled
SWOG Cancer Research Network
National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known if combination chemotherapy is more effective with or without thalidomide for multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without thalidomide in treating patients who have refractory multiple myeloma.
Timeline
- Start
- 2000-04
- Primary completion
- 2003-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thalidomide | Other / unclassified | 800 mg | Oral |
| Background | Cisplatin | Other / unclassified | 15 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 400 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |
| Background | Etoposide | Small molecule | 40 mg/m2 | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | 300 ug | Subcutaneous |
| Background | filgrastim | Protein / enzyme biologic | 480 ug | Subcutaneous |